
Karin A Thursky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5936886/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cytomegalovirus <scp>DNAemia</scp> and disease: currentâ€era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. Internal Medicine Journal, 2022, 52, 1759-1767.	0.8	6
2	Costâ€effectiveness of homeâ€based care of febrile neutropenia in children with cancer. Pediatric Blood and Cancer, 2022, 69, e29469.	1.5	8
3	Opportunities for nurse involvement in surgical antimicrobial stewardship strategies: A qualitative study. International Journal of Nursing Studies, 2022, 128, 104186.	5.6	4
4	The feasibility and generalizability of assessing the appropriateness of antimicrobial prescribing in hospitals: a review of the Australian National Antimicrobial Prescribing Survey. JAC-Antimicrobial Resistance, 2022, 4, dlac012.	2.1	8
5	Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. Journal of Antimicrobial Chemotherapy, 2022, 77, 1508-1524.	3.0	7
6	Prevalence and predictors of poor outcome in children with febrile neutropaenia presenting to the emergency department. EMA - Emergency Medicine Australasia, 2022, 34, 786-793.	1.1	3
7	Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia. Clinical and Translational Immunology, 2022, 11, .	3.8	5
8	[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Haematology,the, 2022, 9, e573-e584.	4.6	15
9	The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. Clinical Infectious Diseases, 2021, 73, 487-496.	5.8	74
	The role of 18Fâ€Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG) Tj ETQq0 C) 0 rgBT /0	verlock 10 Tf
10	with acute leukemia prior to allogeneic hematopoietic cell transplant. Transplant Infectious Disease, 2021, 23, e13547.	1.7	10
11	Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 125-130.	1.3	12
12	Home-based care of low-risk febrile neutropenia in children—an implementation study in a tertiary paediatric hospital. Supportive Care in Cancer, 2021, 29, 1609-1617.	2.2	20
13	CAR-T cell therapy and infection: a review. Expert Review of Anti-Infective Therapy, 2021, 19, 749-758.	4.4	47
14	Electronic health record data for antimicrobial prescribing. Lancet Infectious Diseases, The, 2021, 21, 155-157.	9.1	1
15	Divergent and Convergent Attitudes and Views of General Practitioners and Community Pharmacists to Collaboratively Implement Antimicrobial Stewardship Programs in Australia: A Nationwide Study. Antibiotics, 2021, 10, 47.	3.7	7
16	Development of an antimicrobial stewardship implementation model involving collaboration between general practitioners and pharmacists: GPPAS study in Australian primary care. Primary Health Care Research and Development, 2021, 22, e2.	1.2	5
17	Quality of inpatient antimicrobial use in hematology and oncology patients. Infection Control and Hospital Epidemiology, 2021, 42, 1235-1244.	1.8	11
18	Managing lowâ€risk febrile neutropenia in children in the time of <scp>COVID</scp> â€19: What matters to parents and clinicians. Journal of Paediatrics and Child Health, 2021, 57, 826-834.	0.8	7

#	Article	IF	CITATIONS
19	An international inventory of antimicrobial stewardship (AMS) training programmes for AMS teams. Journal of Antimicrobial Chemotherapy, 2021, 76, 1633-1640.	3.0	8
20	Improving intravenous-to-oral antibiotic switch in children: a team-based audit and implementation approach. BMJ Open Quality, 2021, 10, e001120.	1.1	9
21	Antimicrobial stewardship by Australian community pharmacists: Uptake, collaboration, challenges, and needs. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 158-168.e7.	1.5	13
22	The impact of pharmacistâ€led antifungal stewardship interventions in the hospital setting: a systematic review. Journal of Pharmacy Practice and Research, 2021, 51, 90-105.	0.8	1
23	Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia. Frontiers in Immunology, 2021, 12, 641879.	4.8	8
24	Point Prevalence Survey of Antimicrobial Use in a Malaysian Tertiary Care University Hospital. Antibiotics, 2021, 10, 531.	3.7	13
25	Evaluating the Implementation of a Pilot Quality Improvement Program to Support Appropriate Antimicrobial Prescribing in General Practice. Antibiotics, 2021, 10, 867.	3.7	5
26	Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohort. PLoS ONE, 2021, 16, e0255107.	2.5	4
27	Invasive fungal disease in children with acute myeloid leukaemia: An Australian multicentre 10â€year review. Pediatric Blood and Cancer, 2021, 68, e29275.	1.5	10
28	Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents. EClinicalMedicine, 2021, 40, 101095.	7.1	10
29	Topical antimicrobial prescribing patterns in residents of Australian aged-care facilities: use of a national point prevalence survey to identify opportunities for quality improvement. American Journal of Infection Control, 2021, 49, 1113-1117.	2.3	1
30	Antimicrobial stewardship in Australia: the role of qualitative research in programme development. JAC-Antimicrobial Resistance, 2021, 3, dlab166.	2.1	8
31	The Implementation Challenges of Undertaking National Antimicrobial Usage Surveillance. Clinical Infectious Diseases, 2021, 73, 223-225.	5.8	2
32	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Internal Medicine Journal, 2021, 51, 37-66.	0.8	24
33	Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021. Internal Medicine Journal, 2021, 51, 18-36.	0.8	15
34	Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. Internal Medicine Journal, 2021, 51, 89-117.	0.8	21
35	Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Internal Medicine Journal, 2021, 51, 143-176.	0.8	51
36	Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than <i>Aspergillus</i> in the haematology/oncology setting, 2021. Internal Medicine Journal, 2021, 51, 177-219.	0.8	25

#	Article	IF	CITATIONS
37	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Internal Medicine Journal, 2021, 51, 67-88.	0.8	36
38	A systems thinking approach for antimicrobial stewardship in primary care. Expert Review of Anti-Infective Therapy, 2021, , 1-9.	4.4	4
39	How to start an antimicrobial stewardship programme in a hospital. Clinical Microbiology and Infection, 2020, 26, 447-453.	6.0	41
40	Risk stratification in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine, 2020, 18, 100220.	7.1	34
41	Evaluating the implementability of Antibiotic Surgical Prophylaxis guidelines. Infection, Disease and Health, 2020, 25, 11-21.	1.1	2
42	Factors associated with antimicrobial choice for surgical prophylaxis in Australia. JAC-Antimicrobial Resistance, 2020, 2, dlaa036.	2.1	5
43	Implementation of Effective Antifungal Stewardship in Cancer Patients—A Review of Current Evidence. Current Fungal Infection Reports, 2020, 14, 361-372.	2.6	0
44	Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia. EClinicalMedicine, 2020, 23, 100394.	7.1	28
45	Antibiotic prescribing in surgery: A clinically and socially complex problem in Australia. Infection, Disease and Health, 2020, 25, 309-313.	1.1	5
46	Classification performance of administrative coding data for detection of invasive fungal infection in paediatric cancer patients. PLoS ONE, 2020, 15, e0238889.	2.5	7
47	Identifying targets for improvement using a nationally standardized survey: Surgical antimicrobial prophylaxis in orthopedic surgery. Infection Control and Hospital Epidemiology, 2020, 41, 1419-1428.	1.8	2
48	Aminoglycoside use in paediatric febrile neutropenia – Outcomes from a nationwide prospective cohort study. PLoS ONE, 2020, 15, e0238787.	2.5	11
49	Awareness of Antimicrobial Resistance in the Community: The Role of the WHO in Addressing Consumer Information Needs. Journal of Consumer Health on the Internet, 2020, 24, 391-406.	0.4	1
50	Managing haematology and oncology patients during the <scp>COVID</scp> â€19 pandemic: interim consensus guidance. Medical Journal of Australia, 2020, 212, 481-489.	1.7	107
51	Developing a Clinical Decision Support Tool for Appropriate Antibiotic Prescribing in Australian General Practice: A Simulation Study. Medical Decision Making, 2020, 40, 428-437.	2.4	8
52	Burden of antibiotic allergy labels in Australian aged care residents: Findings from a national point-prevalence survey. Infection Control and Hospital Epidemiology, 2020, 41, 641-644.	1.8	2
53	A Nationwide Survey of Australian General Practitioners on Antimicrobial Stewardship: Awareness, Uptake, Collaboration with Pharmacists and Improvement Strategies. Antibiotics, 2020, 9, 310.	3.7	15
54	Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. Supportive Care in Cancer, 2020, 28, 6023-6034.	2.2	7

#	Article	IF	CITATIONS
55	Sepsis in cancer: a question of definition. Australian and New Zealand Journal of Public Health, 2020, 44, 245.	1.8	4
56	Levofloxacin prophylaxis in patients with myeloma. Lancet Oncology, The, 2020, 21, e67.	10.7	6
57	<i>Candida auris</i> in an Australian health care facility: importance of screening high risk patients. Medical Journal of Australia, 2020, 212, 510.	1.7	6
58	Case for antimicrobial stewardship pharmacy technicians in Australian hospitals. Australian Health Review, 2020, 44, 941.	1.1	0
59	Title is missing!. , 2020, 15, e0238889.		0
60	Title is missing!. , 2020, 15, e0238889.		0
61	Title is missing!. , 2020, 15, e0238889.		Ο
62	Title is missing!. , 2020, 15, e0238889.		0
63	Mold-active prophylaxis in acute leukemia: not enough of a good thing?. Leukemia and Lymphoma, 2019, 60, 2851-2853.	1.3	1
64	Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2151-2153.	3.8	22
65	Appropriateness of Surgical Antimicrobial Prophylaxis Practices in Australia. JAMA Network Open, 2019, 2, e1915003.	5.9	41
66	Antibiotic appropriateness and guideline adherence in hospitalized children: results of a nationwide study. Journal of Antimicrobial Chemotherapy, 2019, 75, 738-746.	3.0	13
67	Influences on surgical antimicrobial prophylaxis decision making by surgical craft groups, anaesthetists, pharmacists and nurses in public and private hospitals. PLoS ONE, 2019, 14, e0225011.	2.5	39
68	Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program. Leukemia and Lymphoma, 2019, 60, 2373-2383.	1.3	11
69	Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. Pharmacoeconomics, 2019, 37, 931-941.	3.3	7
70	Sepsis incidence and mortality are underestimated in Australian intensive care unit administrative data. Medical Journal of Australia, 2019, 210, 188.	1.7	6
71	A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2Âyears. Transplant Infectious Disease, 2019, 21, e13076.	1.7	6
72	Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression. Journal of Clinical Oncology, 2019, 37, 1139-1140.	1.6	14

#	Article	IF	CITATIONS
73	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. Leukemia and Lymphoma, 2019, 60, 2471-2476.	1.3	7
74	Nonneutropenic fever in children with cancer: A scoping review of management and outcome. Pediatric Blood and Cancer, 2019, 66, e27634.	1.5	17
75	Impact of a hospitalâ€wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre. European Journal of Cancer Care, 2019, 28, e13018.	1.5	3
76	How do general practitioners access guidelines and utilise electronic medical records to make clinical decisions on antibiotic use? Results from an Australian qualitative study. BMJ Open, 2019, 9, e028329.	1.9	26
77	High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 1572-1575.	1.3	19
78	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. Internal Medicine Journal, 2019, 49, 615-621.	0.8	6
79	Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach. Clinical Microbiology and Infection, 2019, 25, 20-25.	6.0	125
80	Natural killer cell function predicts severe infection in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 166-177.	4.7	20
81	The 2018 Aged Care National Antimicrobial Prescribing Survey: results show room for improvement. Australian Prescriber, 2019, 42, 200-203.	1.0	2
82	Title is missing!. , 2019, 14, e0225011.		0
83	Title is missing!. , 2019, 14, e0225011.		0
84	Title is missing!. , 2019, 14, e0225011.		0
85	Title is missing!. , 2019, 14, e0225011.		0
86	Seroresponses and safety of 13â€valent pneumococcal conjugate vaccination in kidney transplant recipients. Transplant Infectious Disease, 2018, 20, e12866.	1.7	22
87	Management of fever and neutropenia in children with cancer: A survey of Australian and New Zealand practice. Journal of Paediatrics and Child Health, 2018, 54, 761-769.	0.8	20
88	Barriers to and enablers of implementing antimicrobial stewardship programs in veterinary practices. Journal of Veterinary Internal Medicine, 2018, 32, 1092-1099.	1.6	77
89	The Combined Utility of ExÂVivo IFN-Î ³ Release Enzyme-Linked ImmunoSpot Assay and InÂVivo SkinÂTesting in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1287-1296.e1.	3.8	47
90	Antimicrobials used for surgical prophylaxis by equine veterinary practitioners in Australia. Equine Veterinary Journal, 2018, 50, 65-72.	1.7	23

#	Article	IF	CITATIONS
91	Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Supportive Care in Cancer, 2018, 26, 997-1003.	2.2	18
92	External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules. Pediatric Infectious Disease Journal, 2018, 37, 329-335.	2.0	15
93	The clinical utility of fluorodeoxyglucoseâ€positron emission tomography for investigation of fever in immunocompromised children. Journal of Paediatrics and Child Health, 2018, 54, 487-492.	0.8	9
94	Population wide assessment of antimicrobial use in dogs and cats using a novel data source – A cohort study using pet insurance data. Veterinary Microbiology, 2018, 225, 34-39.	1.9	40
95	Antifungal stewardship: developments in the field. Current Opinion in Infectious Diseases, 2018, 31, 490-498.	3.1	25
96	Prevalence of infections and antimicrobial prescribing in Australian aged care facilities: Evaluation of modifiable and nonmodifiable determinants. American Journal of Infection Control, 2018, 46, 1148-1153.	2.3	10
97	How antibiotic allergy labels may be harming our most vulnerable patients. Medical Journal of Australia, 2018, 208, 469-470.	1.7	15
98	Surgical antibiotic prophylaxis – The evidence and understanding its impact on consensus guidelines. Infection, Disease and Health, 2018, 23, 179-188.	1.1	7
99	Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer. Journal of Antimicrobial Chemotherapy, 2018, 73, 3209-3211.	3.0	6
100	Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Quality, 2018, 7, e000355.	1.1	41
101	Meeting the challenge for effective antimicrobial stewardship programs in regional, rural and remote hospitals - what can we learn from the published literature?. Rural and Remote Health, 2018, 18, 4442.	0.5	21
102	Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study. Supportive Care in Cancer, 2017, 25, 1923-1930.	2.2	22
103	Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. Clinical Infectious Diseases, 2017, 65, 166-174.	5.8	106
104	Antimicrobials used for surgical prophylaxis by companion animal veterinarians in Australia. Veterinary Microbiology, 2017, 203, 301-307.	1.9	25
105	Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study. British Journal of Cancer, 2017, 117, 171-178.	6.4	31
106	Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia and Lymphoma, 2017, 58, 2379-2386.	1.3	21
107	What, where and why: exploring fluorodeoxyglucose-PET's ability to localise and differentiate infection from cancer. Current Opinion in Infectious Diseases, 2017, 30, 552-564.	3.1	12
108	The 3 Cs of Antibiotic Allergy—Classification, Cross-Reactivity, and Collaboration. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1532-1542.	3.8	60

#	Article	IF	CITATIONS
109	Crossâ€sectional study of antimicrobials used for surgical prophylaxis by bovine veterinary practitioners in Australia. Veterinary Record, 2017, 181, 426-426.	0.3	14
110	Human resources estimates and funding for antibiotic stewardship teams are urgently needed. Clinical Microbiology and Infection, 2017, 23, 785-787.	6.0	74
111	Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma. Scientific Reports, 2017, 7, 4395.	3.3	19
112	Antimicrobial stewardship in regional, rural and remote hospitals: Finding the X factor. Infection, Disease and Health, 2017, 22, S4.	1.1	1
113	Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. Frontiers in Immunology, 2017, 8, 1247.	4.8	10
114	The Use of Computerized Decision Support Systems to Support Antimicrobial Stewardship Programs. , 2017, , 99-114.		2
115	Antimicrobial Stewardship in Australia. , 2017, , 247-249.		0
116	Surgical antimicrobial prophylaxis. Australian Prescriber, 2017, 40, 225-229.	1.0	26
117	Toward Electronic Surveillance of Invasive Mold Diseases in Hematology-Oncology Patients: An Expert System Combining Natural Language Processing of Chest Computed Tomography Reports, Microbiology, and Antifungal Drug Data. JCO Clinical Cancer Informatics, 2017, 1, 1-10.	2.1	14
118	Antimicrobial knowledge and confidence amongst final year medical students in Australia. PLoS ONE, 2017, 12, e0182460.	2.5	29
119	Antimicrobial use in Australian hospitals: how much and how appropriate?. Medical Journal of Australia, 2016, 205, S16-S20.	1.7	20
120	Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. Open Forum Infectious Diseases, 2016, 3, ofw153.	0.9	57
121	Invasive fungal infections in ALL: a new †̃growth' area. Leukemia and Lymphoma, 2016, 57, 1985-1987.	1.3	1
122	Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. European Journal of Cancer, 2016, 67, 21-37.	2.8	49
123	The epidemiology of <i>Clostridium difficile</i> infection in patients with cancer. Expert Review of Anti-Infective Therapy, 2016, 14, 1077-1085.	4.4	19
124	Azole Antifungal Agents. , 2016, , 77-96.		0
125	Evaluating antimicrobial therapy: How reliable are remote assessors?. Infection, Disease and Health, 2016, 21, 3-10.	1.1	11
126	Isavuconazole: a role for the newest broad-spectrum triazole. Lancet, The, 2016, 387, 726-728.	13.7	18

#	Article	IF	CITATIONS
127	Antimicrobial allergy â€`labels' drive inappropriate antimicrobial prescribing: lessons for stewardship. Journal of Antimicrobial Chemotherapy, 2016, 71, 1715-1722.	3.0	95
128	Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica, 2015, 100, e462-e466.	3.5	30
129	The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients. Antimicrobial Resistance and Infection Control, 2015, 4, 23.	4.1	52
130	Can mortality of cancer patients with fever and neutropenia be improved?. Current Opinion in Infectious Diseases, 2015, 28, 505-513.	3.1	34
131	Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. British Journal of Haematology, 2015, 171, 100-108.	2.5	94
132	The treatment of nursing homeâ€acquired pneumonia using a medically intensive Hospital in the Home service. Medical Journal of Australia, 2015, 203, 441-442.	1.7	12
133	Implementing antimicrobial stewardship in the Australian private hospital system: a qualitative study. Australian Health Review, 2015, 39, 315.	1.1	29
134	Core outcomes and definitions for pediatric fever and neutropenia research: A consensus statement from an international panel. Pediatric Blood and Cancer, 2015, 62, 483-489.	1.5	55
135	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Supportive Care in Cancer, 2015, 23, 1901-1906.	2.2	30
136	Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool. Journal of Antimicrobial Chemotherapy, 2015, 70, 1912-1918.	3.0	66
137	Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica, 2015, 100, e28-e31.	3.5	62
138	Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. Journal of Antimicrobial Chemotherapy, 2015, 70, 1161-5.	3.0	26
139	The prevention and management of infections due to multidrug resistant organisms in haematology patients. British Journal of Clinical Pharmacology, 2015, 79, 195-207.	2.4	41
140	Improving the outcome of bloodstream infection in patients with hematological malignancies: looking beyond antibiotics. Leukemia and Lymphoma, 2015, 56, 3243-3245.	1.3	2
141	A mixed methods study of the barriers and enablers in implementing antimicrobial stewardship programmes in Australian regional and rural hospitals. Journal of Antimicrobial Chemotherapy, 2015, 70, 2665-2670.	3.0	44
142	<i>Candida glabrata</i> fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. Leukemia and Lymphoma, 2015, 56, 3442-3444.	1.3	6
143	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leukemia and Lymphoma, 2015, 56, 157-162.	1.3	11
144	Automatic detection of patients with invasive fungal disease from free-text computed tomography (CT) scans. Journal of Biomedical Informatics, 2015, 53, 251-260.	4.3	23

#	Article	IF	CITATIONS
145	Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: A systematic review and meta-analysis. Critical Reviews in Microbiology, 2015, 41, 124-134.	6.1	100
146	Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Internal Medicine Journal, 2014, 44, 1333-1349.	0.8	87
147	Attitudes towards antimicrobial stewardship: results from a large private hospital in Australia. Healthcare Infection, 2014, 19, 89-94.	0.6	51
148	Disseminated <i>Scedosporium prolificans</i> infection in an â€~extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. Mycoses, 2014, 57, 572-576.	4.0	23
149	Are they protected? Immunity to vaccineâ€preventable diseases in healthcare workers at an Australian hospital. Australian and New Zealand Journal of Public Health, 2014, 38, 83-86.	1.8	10
150	Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leukemia and Lymphoma, 2014, 55, 938-939.	1.3	13
151	Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (<scp>HSCT</scp>) in <scp>A</scp> ustralia and <scp>N</scp> ealand. Internal Medicine Journal, 2014, 44, 1277-1282.	0.8	25
152	Consensus guidelines for diagnosis, prophylaxis and management of <scp><i>P</i></scp> <i>neumocystis jirovecii</i> pneumonia in patients with haematological and solid malignancies, 2014. Internal Medicine Journal, 2014, 44, 1350-1363.	0.8	169
153	Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagnostic Microbiology and Infectious Disease, 2014, 79, 322-327.	1.8	54
154	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. Blood Reviews, 2014, 28, 75-86.	5.7	52
155	Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: Clinical significance of quantitative polymerase chain reaction. Medical Mycology, 2014, 52, 427-432.	0.7	10
156	Antimicrobial stewardship activities: a survey of Queensland hospitals. Australian Health Review, 2014, 38, 557.	1.1	30
157	Facilitating Surveillance of Pulmonary Invasive Mold Diseases in Patients with Haematological Malignancies by Screening Computed Tomography Reports Using Natural Language Processing. PLoS ONE, 2014, 9, e107797.	2.5	15
158	Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 1669-1678.	3.0	19
159	Outpatient Therapy for Fever and Neutropenia Is Safe but Implementation Is the Key. Journal of Clinical Oncology, 2013, 31, 1128-1129.	1.6	8
160	Lateâ€onset <i><scp>P</scp>neumocystis jirovecii</i> pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. European Journal of Haematology, 2013, 91, 157-163.	2.2	23
161	Antimicrobial stewardship in Victorian hospitals: a statewide survey to identify current gaps. Medical Journal of Australia, 2013, 199, 692-695.	1.7	26
162	Dosing of antibiotics in obesity. Current Opinion in Infectious Diseases, 2012, 25, 634-649.	3.1	130

#	Article	IF	CITATIONS
163	The case for antifungal stewardship. Current Opinion in Infectious Diseases, 2012, 25, 107-115.	3.1	115
164	Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica, 2012, 97, 459-463.	3.5	99
165	Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leukemia and Lymphoma, 2012, 53, 1889-1895.	1.3	23
166	Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy. British Journal of Radiology, 2012, 85, 1011-1017.	2.2	45
167	Public disclosure of health careâ€associated infections in Australia: quality improvement or parody?. Medical Journal of Australia, 2012, 197, 29-29.	1.7	7
168	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1348-1355.	6.4	31
169	Clinically important detection of infection as an â€`incidental' finding during cancer staging using FDGâ€PET/CT. Internal Medicine Journal, 2012, 42, 176-183.	0.8	17
170	Fluoroquinolone prophylaxis: a word of caution. Leukemia and Lymphoma, 2011, 52, 5-6.	1.3	14
171	Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal, 2011, 41, 75-81.	0.8	27
172	Use of risk stratification to guide ambulatory management of neutropenic fever. Internal Medicine Journal, 2011, 41, 82-89.	0.8	30
173	Use of empiric antimicrobial therapy in neutropenic fever. Internal Medicine Journal, 2011, 41, 90-101.	0.8	67
174	Use of antibacterial prophylaxis for patients with neutropenia. Internal Medicine Journal, 2011, 41, 102-109.	0.8	45
175	An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Internal Medicine Journal, 2011, 41, 110-120.	0.8	22
176	The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset. Internal Medicine Journal, 2011, 41, 121-129.	0.8	28
177	<i>Legionella pneumophila</i> lung abscess associated with immune suppression. Internal Medicine Journal, 2011, 41, 715-721.	0.8	22
178	Epidemiology of Infections Acquired in Intensive Care Units. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 115-138.	2.1	75
179	Current Hepatitis B Screening Practices and Clinical Experience of Reactivation in Patients Undergoing Chemotherapy for Solid Tumors: A Nationwide Survey of Medical Oncologists. Journal of Oncology Practice, 2011, 7, 141-147.	2.5	45
180	<i>Stenotrophomonas maltophilia</i> : emerging disease patterns and challenges for treatment. Expert Review of Anti-Infective Therapy, 2011, 9, 471-488.	4.4	85

#	Article	IF	CITATIONS
181	A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Australian Health Review, 2011, 35, 491.	1.1	20
182	Visceral leishmaniasis due to Leishmania donovani in a patient with advanced HIV infection. Medical Journal of Australia, 2010, 192, 474-475.	1.7	2
183	Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. Journal of Antimicrobial Chemotherapy, 2010, 65, 1052-1061.	3.0	30
184	Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. Journal of Antimicrobial Chemotherapy, 2010, 65, 1042-1051.	3.0	148
185	Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. Journal of Antimicrobial Chemotherapy, 2010, 65, 1062-1069.	3.0	96
186	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. Emerging Infectious Diseases, 2010, 16, 1068-1075.	4.3	108
187	Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leukemia and Lymphoma, 2010, 51, 1592-1595.	1.3	8
188	Piperacillin–Tazobactam. , 2010, , 238-254.		1
189	Mezlocillin, Azlocillin, Apalcillin and Piperacillin. , 2010, , 135-151.		0
190	A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. Journal of Infection, 2009, 59, 19-27.	3.3	116
191	Guidance DS: A web-based clinical decision support system for antimicrobial stewardship in hospitals. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2009, 42, 354-358.	0.4	0
192	Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Internal Medicine Journal, 2008, 38, 468-476.	0.8	31
193	Recommendations for the treatment of established fungal infections. Internal Medicine Journal, 2008, 38, 496-520.	0.8	58
194	Posaconazole as first line treatment for disseminated zygomycosis. Mycoses, 2008, 51, 542-545.	4.0	33
195	Improving antibiotic prescribing for adults with community acquired pneumonia: Does a computerised decision support system achieve more than academic detailing alone? – a time series analysis. BMC Medical Informatics and Decision Making, 2008, 8, 35.	3.0	59
196	Virulence determinants in vancomycin-resistant Enterococcus faecium vanB: clonal distribution, prevalence and significance of esp and hyl in Australian patients with haematological disorders. Journal of Hospital Infection, 2008, 68, 137-144.	2.9	27
197	Surveillance for Catheter-Associated Bloodstream Infection in Hematology Units: Quantifying the Characteristics of a Practical Case Definition. Infection Control and Hospital Epidemiology, 2008, 29, 358-360.	1.8	15
198	Electronic antibiotic stewardshipreduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting. Journal of Antimicrobial Chemotherapy, 2008, 62, 608-616.	3.0	124

#	Article	IF	CITATIONS
199	Implementation of a computerised antimicrobial approval system in a hospital environment: lessons learned. Healthcare Infection, 2008, 13, 89-93.	0.6	0
200	Infection with <i>Scedosporium apiospermum</i> and <i>S</i> . <i>prolificans</i> , Australia. Emerging Infectious Diseases, 2007, 13, 1170-1177.	4.3	78
201	A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2007, 40, 157-163.	2.4	29
202	Identifying severe communityâ€acquired pneumonia in the emergency department: A simple clinical prediction tool. EMA - Emergency Medicine Australasia, 2007, 19, 418-426.	1.1	59
203	User-centered design techniques for a computerised antibiotic decision support system in an intensive care unit. International Journal of Medical Informatics, 2007, 76, 760-768.	3.3	72
204	Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. European Journal of Haematology, 2007, 79, 226-233.	2.2	77
205	Use of computerized decision support systems to improve antibiotic prescribing. Expert Review of Anti-Infective Therapy, 2006, 4, 491-507.	4.4	48
206	Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention. Leukemia and Lymphoma, 2006, 47, 2435-2436.	1.3	5
207	Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. British Journal of Haematology, 2006, 132, 3-12.	2.5	178
208	Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. International Journal for Quality in Health Care, 2006, 18, 224-231.	1.8	74
209	A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax, 2006, 61, 419-424.	5.6	178
210	An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer, 2005, 92, 867-872.	6.4	70
211	Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica, 2005, 90, 1672-9.	3.5	53
212	Are the Australian guidelines asking too much of the Pneumonia Severity Index (PSI)?. Medical Journal of Australia, 2004, 180, 486-487.	1.7	6
213	Are the Australian guidelines asking too much of the Pneumonia Severity Index (PSI)?. Medical Journal of Australia, 2004, 181, 515-516.	1.7	0
214	Guidelines for the use of antifungal agents in the treatment of invasiveCandidaand mould infections. Internal Medicine Journal, 2004, 34, 192-200.	0.8	46
215	Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 115-121.	2.4	75
216	Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting Blood, 2004, 104, 3837-3837.	1.4	1

#	Article	IF	CITATIONS
217	Working towards a simple case definition for influenza surveillance. Journal of Clinical Virology, 2003, 27, 170-179.	3.1	100
218	Epidemiology, Prevalence, and Sites of Infections in Intensive Care Units. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 003-022.	2.1	47